Sanofi Tops Pfizer As Number One For Global Pharma Sales
08-Nov-2011
- United Kingdom
“The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years,” commented Dr Jonathan de Pass, chief executive of EvaluatePharma. “Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest.”
Market Rank
|
Rx & OTC pharma sales ($bn)
|
||||||||
2011 | 2012 | 2014 | 2016 | 2011 | 2012 | 2014 | 2016 | Annual growth
2011-16 |
|
Sanofi | 3 | 1 | 1 | 1 | 47.9 | 51.6 | 55.4 | 58.4 | 4% |
Novartis | 2 | 2 | 2 | 2 | 49.5 | 49.9 | 52.2 | 54.8 | 2% |
Pfizer | 1 | 3 | 3 | 3 | 54.1 | 49.8 | 49.7 | 51.9 | (1%) |
GlaxoSmithKline | 5 | 6 | 5 | 4 | 39.3 | 41.2 | 45.6 | 50.9 | 5% |
Roche | 6 | 4 | 4 | 5 | 39.1 | 44.1 | 46.3 | 49.0 | 5% |
Merck & Co | 4 | 5 | 6 | 6 | 42.1 | 41.9 | 41.4 | 43.4 | 1% |
Johnson & Johnson | 8 | 8 | 7 | 7 | 24.8 | 26.5 | 29.4 | 31.5 | 5% |
AstraZeneca | 7 | 7 | 8 | 8 | 32.0 | 29.2 | 27.5 | 25.7 | (4%) |
Teva | 12 | 10 | 10 | 9 | 17.4 | 20.3 | 22.5 | 24.4 | 7% |
Abbott Laboratories | 9 | 9 | 9 | 10 | 22.5 | 23.5 | 23.7 | 24.3 | 2% |
Bayer | 11 | 12 | 11 | 11 | 18.9 | 19.7 | 21.7 | 23.4 | 4% |
Takeda | 14 | 13 | 12 | 12 | 17.0 | 18.2 | 18.7 | 20.2 | 3% |
Bristol-Myers Squibb | 13 | 16 | 17 | 13 | 17.1 | 14.2 | 15.4 | 18.9 | 2% |
Novo Nordisk | 17 | 17 | 15 | 14 | 12.3 | 13.6 | 16.4 | 18.9 | 9% |
Eli Lilly | 10 | 11 | 14 | 13 | 21.5 | 20.1 | 17.6 | 17.9 | (4%) |
Most read news
Topics
Pfizer
Sanofi-aventis
Novartis
GlaxoSmithKline
Roche
MSD
Johnson & Johnson
AstraZeneca
TEVA
Abbott
Bayer
Takeda
Bristol-Myers Squibb
Novo Nordisk
Eli Lilly
Genzyme
Organizations
College Hill
Evaluate
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.